Laryngeal Neoplasms clinical trials
The registry lists 257 studies for Laryngeal Neoplasms across more than 10 countries. 68 are recruiting or about to start. 92 of them are mainly about Laryngeal Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Get an email when these change. Save the Laryngeal Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
National Cancer Institute (NCI) (16) · M.D. Anderson Cancer Center (7) · Mayo Clinic (6) · Roswell Park Cancer Institute (6) · Memorial Sloan Kettering Cancer Center (5) · Fudan University (4) · Wake Forest University Health Sciences (4) · Washington University School of Medicine (4)
What is being tested here
Drugs under test in Laryngeal Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Cisplatin | 4 | 3 | 19 |
| Toripalimab | 3 | 0 | 3 |
| Cetuximab | 2 | 2 | 12 |
| Paclitaxel | 2 | 0 | 9 |
| Carboplatin | 2 | 2 | 8 |
| Pembrolizumab | 2 | 0 | 5 |
| Docetaxel | 1 | 2 | 9 |
| Celecoxib | 1 | 0 | 4 |
| Ipatasertib | 1 | 0 | 2 |
| Cemiplimab | 1 | 0 | 2 |
Drug classes tested here Immune checkpoint inhibitors 8 open · Antimitotic agents 3 open · Antimetabolites 2 open · Tyrosine kinase inhibitors (TKIs) 2 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest
- Dec 2026Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer · Centre hospitalier de l'Université de Montréal (CHUM)
- Dec 2026Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck · Ohio State University Comprehensive Cancer Center
- Dec 2026Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy · University Hospital Freiburg
- Jan 2027BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study · National Cancer Institute (NCI)
- Jan 2027Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer · NRG Oncology
- Jan 2027Quality of Life and Functional Outcomes in Laryngeal Cancer Patients · Saglik Bilimleri Universitesi
- Apr 2027Telemedicine Follow-Up for Early Laryngeal Cancer: a Randomized Controlled Trial Comparing Care Close to Home Versus Standard of Care · University Medical Center Groningen
- Jun 2027Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck · National Cancer Institute (NCI)
- Jun 2027Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose Radiotherapy · Maria Sklodowska-Curie National Research Institute of Oncology
- Jun 2027Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" · M.D. Anderson Cancer Center
Who these studies take
Of the 56 Laryngeal Neoplasms studies recruiting now, 41 (73%) set no upper age limit and 6 (11%) stop at 75 or younger. 3 (5%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (5%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (5%) | 3 (5%) |
| 18 | 53 (95%) | 53 (95%) |
| 30 | 55 (98%) | 55 (98%) |
| 40 | 55 (98%) | 55 (98%) |
| 50 | 55 (98%) | 55 (98%) |
| 65 | 56 (100%) | 56 (100%) |
| 75 | 54 (96%) | 54 (96%) |
| 85 | 48 (86%) | 48 (86%) |
Across all 257 studies, recruiting or not: 13% stop at 75 or younger and 1% at 65; 10% take children; <1% are for women only and <1% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Laryngeal Neoplasms studies take
Of 30 phase 2 interventional studies under Laryngeal Neoplasms, half reached primary completion within 72 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 57 mo32–62 · 14 studies | — | — |
| Phase 2 | 72 mo55–82 · 30 studies | — | — |
| Interventional, no phase | 71 mo27–119 · 39 studies | — | — |
| Observational | 44 mo24–172 · 27 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 14, 2026.
Started recruiting1
Newly registered3
- Induction Chemoimmunotherapy to Prevent Laryngectomy in Advanced Laryngeal Cancer and Hypopharyngeal CancerNov 9, 2026NCT07923877
- Removing the Planning Tumor Volume From Radiation Therapy for the Treatment of Head and Neck Squamous Cell CarcinomaNov 9, 2026NCT07926906
- TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell CarcinomaOct 27, 2026NCT07898124
Studies
Recruiting first, then most recently updated. Showing 50 of 257. Browse all 257 → or search them.
- Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck CancerRecruitingNCT05172245Phase 12 countries
- Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentRecruitingNCT06589804Phase 31 country
- BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyRecruitingNCT05136196Phase 21 country
- Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate CancerRecruitingNCT07667400Phase 1/21 country
- Removing the Planning Tumor Volume From Radiation Therapy for the Treatment of Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07926906Not applicable1 country
- Induction Chemoimmunotherapy to Prevent Laryngectomy in Advanced Laryngeal Cancer and Hypopharyngeal CancerNot yet recruitingNCT07923877Phase 21 country
- PET/CT Assessment of Radiation-Induced Vascular Complications in Head and Neck CancerRecruitingNCT06914999Early Phase 11 country
- Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal VolunteersRecruitingNCT009004191 country
- Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)Not yet recruitingNCT07552558Phase 1/21 country
- Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell CarcinomaRecruitingNCT07156227Phase 11 country
- TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell CarcinomaRecruitingNCT07898124Phase 11 country
- Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck CancerRecruitingNCT07195734Phase 21 country
- Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerRecruitingNCT06980038Phase 21 country
- Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck CancerRecruitingNCT030101501 country
- Intraoperative Methadone for the Management of Postoperative Pain in Patients With Head and Neck CancersRecruitingNCT07857655Phase 41 country
- Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States PopulationRecruitingNCT06997068Phase 21 country
- Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone SurgeryRecruitingNCT02734537Phase 21 country
- A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous LesionsRecruitingNCT075325381 country
- Thermotherapy for Head and Neck Cancer PatientsRecruitingNCT07690618Phase 11 country
- DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.RecruitingNCT07440290Phase 2/31 country
- Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck CancerRecruitingNCT06532279Phase 21 country
- Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or RadiationRecruitingNCT06662058Not applicable1 country
- Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"RecruitingNCT01365169Not applicable1 country
- Integrated Cancer Repository for Cancer ResearchRecruitingNCT020126991 country
- The Role of the Free/Pedunculated Flap in Total Laryngectomy After (Chemo-)Radiotherapy Failure for Laryngeal Carcinoma: Impact on the Risk of Pharyngocutaneous Fistula (PCF)RecruitingNCT062870341 country
- p-PHOTOLARYNX- ANTHEM: Photon-Counting CT in Laryngeal Cancer StagingEnrolling by invitationNCT076031671 country
- Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck CarcinomaRecruitingNCT06706401Phase 31 country
- Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)RecruitingNCT07209189Phase 21 country
- Quality of Life and Functional Outcomes in Laryngeal Cancer PatientsNot yet recruitingNCT07320820
- Workshops and Exchange Groups for Laryngectomized PatientsRecruitingNCT060776431 country
- TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell CancerRecruitingNCT06868433Phase 11 country
- A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)RecruitingNCT07063212Phase 21 country
- Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP TrialRecruitingNCT06636734Phase 21 country
- Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and NeckRecruitingNCT01473784Not applicable1 country
- Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCCNot yet recruitingNCT07400094Phase 21 country
- CONFIRM: Magnetic Resonance Guided Radiation TherapyRecruitingNCT04368702Not applicable1 country
- Precision Medicine: MRI-Guided Stereotactic Ablative Radiotherapy (MRI-SABR) for Early-Stage Glottic Laryngeal CancerRecruitingNCT07391345Not applicable1 country
- Validation of End-to-End Difficult Airway Pathway Planning Algorithm (EAP-LC)Not yet recruitingNCT07324317
- Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant TherapyRecruitingNCT05793151Not applicable1 country
- Clinical Treatments in Specialized Diseases of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC)RecruitingNCT049086961 country
- CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE)Not yet recruitingNCT07254962Phase 2
- Phase II Randomized Study of Hypofractionated Versus Conventional RadiotherapyRecruitingNCT06080503Not applicable1 country
- DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.RecruitingNCT05768178Phase 2/31 country
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruitingNCT034527742 countries
- VoiceS: Voice Quality After Transoral CO2-Laser Surgery Versus Single Vocal Cord Irradiation for Larynx CancerRecruitingNCT04057209Not applicable3 countries
- Telemedicine Follow-Up for Early Laryngeal Cancer: a Randomized Controlled Trial Comparing Care Close to Home Versus Standard of CareRecruitingNCT06940505Not applicable1 country
- The Voice as a Tool to Detect Recurrence of Laryngeal and Hypopharyngeal CancerRecruitingNCT058940701 country
- Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal CarcinomaNot yet recruitingNCT06957938Phase 31 country
- Special Care Patterns for Elderly HNSCC Patients Undergoing RadiotherapyRecruitingNCT053376315 countries
- The Relationship Between the Differential Expression of FosB Protein in Laryngeal Cancer Tissues and Clinical PrognosisNot yet recruitingNCT068367651 country